Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage --- United States, October-December 2009.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Jan 22;59(2):44-8.

2.

Optimizing infectious disease interventions during an emerging epidemic.

Wallinga J, van Boven M, Lipsitch M.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):923-8. doi: 10.1073/pnas.0908491107. Epub 2009 Dec 28.

3.

Optimal pandemic influenza vaccine allocation strategies for the canadian population.

Tuite A, Fisman DN, Kwong JC, Greer A.

PLoS Curr. 2010 Jan 4;2:RRN1144.

4.

Optimizing allocation for a delayed influenza vaccination campaign.

Medlock J, Meyers LA, Galvani A.

Version 2. PLoS Curr. 2009 Dec 9 [revised 2009 Dec 13];1:RRN1134.

5.

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Nissen M, Marshall H, Booy R, Heron L, Hartel G, Lai M, Basser R, Gittleson C, Greenberg M.

JAMA. 2010 Jan 6;303(1):37-46. doi: 10.1001/jama.2009.1911. Epub 2009 Dec 21.

PMID:
20026597
6.

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M.

Lancet. 2010 Jan 2;375(9708):41-8. doi: 10.1016/S0140-6736(09)62026-2. Epub 2009 Dec 15.

PMID:
20018365
8.

Distribution of vaccine/antivirals and the 'least spread line' in a stratified population.

Goldstein E, Apolloni A, Lewis B, Miller JC, Macauley M, Eubank S, Lipsitch M, Wallinga J.

J R Soc Interface. 2010 May 6;7(46):755-64. doi: 10.1098/rsif.2009.0393. Epub 2009 Oct 14.

9.

Modelling mitigation strategies for pandemic (H1N1) 2009.

Gojovic MZ, Sander B, Fisman D, Krahn MD, Bauch CT.

CMAJ. 2009 Nov 10;181(10):673-80. doi: 10.1503/cmaj.091641. Epub 2009 Oct 13.

10.

The transmissibility and control of pandemic influenza A (H1N1) virus.

Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt L, Potter G, Kenah E, Longini IM Jr.

Science. 2009 Oct 30;326(5953):729-33. doi: 10.1126/science.1177373. Epub 2009 Sep 10.

11.

Seasonal transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility.

Balcan D, Hu H, Goncalves B, Bajardi P, Poletto C, Ramasco JJ, Paolotti D, Perra N, Tizzoni M, Van den Broeck W, Colizza V, Vespignani A.

BMC Med. 2009 Sep 10;7:45. doi: 10.1186/1741-7015-7-45.

12.

Optimizing influenza vaccine distribution.

Medlock J, Galvani AP.

Science. 2009 Sep 25;325(5948):1705-8. doi: 10.1126/science.1175570. Epub 2009 Aug 20.

13.

Pandemic potential of a strain of influenza A (H1N1): early findings.

Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F, Ghani AC, Ferguson NM, Rambaut A, Pybus OG, Lopez-Gatell H, Alpuche-Aranda CM, Chapela IB, Zavala EP, Guevara DM, Checchi F, Garcia E, Hugonnet S, Roth C; WHO Rapid Pandemic Assessment Collaboration.

Science. 2009 Jun 19;324(5934):1557-61. doi: 10.1126/science.1176062. Epub 2009 May 11.

14.

Optimal allocation of pandemic influenza vaccine depends on age, risk and timing.

Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J.

Vaccine. 2008 Jul 4;26(29-30):3742-9. doi: 10.1016/j.vaccine.2008.04.043. Epub 2008 May 7.

PMID:
18524428
15.

Simple criteria for finding (nearly) optimal vaccination strategies.

Tennenbaum S.

J Theor Biol. 2008 Feb 21;250(4):673-83. Epub 2007 Oct 24.

PMID:
18076910
16.

Vaccinating to protect a vulnerable subpopulation.

Dushoff J, Plotkin JB, Viboud C, Simonsen L, Miller M, Loeb M, Earn DJ.

PLoS Med. 2007 May;4(5):e174.

17.

A comparative analysis of influenza vaccination programs.

Bansal S, Pourbohloul B, Meyers LA.

PLoS Med. 2006 Oct;3(10):e387.

18.

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP.

Pediatrics. 2005 Sep;116(3):e397-407.

19.

Strategy for distribution of influenza vaccine to high-risk groups and children.

Longini IM Jr, Halloran ME.

Am J Epidemiol. 2005 Feb 15;161(4):303-6.

20.

Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission.

van den Driessche P, Watmough J.

Math Biosci. 2002 Nov-Dec;180:29-48.

PMID:
12387915
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk